ANI Pharmaceuticals (NASDAQ:ANIP) Announces Earnings Results, Beats Estimates By $0.22 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) issued its quarterly earnings data on Friday. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.41 by $0.22, RTT News reports. The business had revenue of $190.60 million during the quarter, compared to analysts’ expectations of $175.36 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business’s revenue was up 44.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.04 EPS. ANI Pharmaceuticals updated its FY25 guidance to $6.12-6.49 EPS.

ANI Pharmaceuticals Stock Up 12.3 %

Shares of ANIP stock traded up $6.74 during trading hours on Friday, reaching $61.32. The company had a trading volume of 322,017 shares, compared to its average volume of 199,757. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $70.81. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -111.54 and a beta of 0.74. The business has a fifty day simple moving average of $57.06 and a 200-day simple moving average of $58.13. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

Analyst Upgrades and Downgrades

ANIP has been the topic of several recent analyst reports. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Finally, Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $77.71.

Insiders Place Their Bets

In other news, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the sale, the senior vice president now owns 49,059 shares in the company, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,300 shares of company stock valued at $584,009. Corporate insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.